Lantus Solostar

Insulin glargine, the active ingredient in Lantus Solostar, is a long‑acting insulin analog presented as a solution for subcutaneous use. It provides basal insulin coverage for patients with diabetes mellitus type 1 and type 2.

GNH USA supplies Lantus Solostar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lantus Solostar is a basal insulin that acts on the glucose regulation pathway to maintain steady blood‑sugar levels.

Diabetes mellitus type 1: provides long‑acting basal insulin to control fasting glucose. Diabetes mellitus type 2: supplies basal insulin support when oral agents are insufficient.

Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if dosing is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase due to improved glucose utilization.

Serious or Rare Side Effects: - Severe hypoglycemia: can lead to loss of consciousness or seizures. - Allergic reactions: rash, urticaria, or angioedema. - Anaphylaxis: rare but life‑threatening systemic allergic response. - Lipodystrophy: abnormal fat distribution at injection sites. - Edema: fluid retention causing swelling of extremities.

When using Lantus Solostar, consider the following precautions: - Dose adjustment: titrate based on regular glucose monitoring and clinical response. - Renal impairment: monitor closely as insulin clearance may be reduced. - Hypoglycemia risk: educate patients on recognizing and treating low blood sugar. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lantus Solostar may interact with other medications as follows:

Major Interactions (Avoid): - Sulfonylureas: combined use can markedly increase hypoglycemia risk. - Beta‑blockers: may mask typical hypoglycemia symptoms, complicating detection.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance insulin sensitivity, requiring dose review. - Thiazide diuretics: can raise blood glucose, potentially altering insulin needs. - Oral contraceptives: may affect insulin requirements, necessitating monitoring.